Lack of the effect of lobeglitazone, a peroxisome proliferator-activated receptor-γ agonist, on the pharmacokinetics and pharmacodynamics of warfarin
Jin Ah Jung,1 Soo-Yun Lee,2 Tae-Eun Kim,3 Jung-Ryul Kim,1 Chin Kim,4 Wooseong Huh,1,5 Jae-Wook Ko1,2 1Department of Clinical Pharmacology and Therapeutics, Samsung Medical Center, 2Department of Health Sciences and Technology, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunk...
Main Authors: | Jung JA, Lee SY, Kim TE, Kim JR, Kim C, Huh W, Ko JW |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2015-03-01
|
Series: | Drug Design, Development and Therapy |
Online Access: | http://www.dovepress.com/lack-of-the-effect-of-lobeglitazone-a-peroxisome-proliferator-activate-peer-reviewed-article-DDDT |
Similar Items
-
No Relevant Pharmacokinetic Drug–Drug Interaction Between the Sodium-Glucose Co-Transporter-2 Inhibitor Empagliflozin and Lobeglitazone, a Peroxisome Proliferator-Activated Receptor-γ Agonist, in Healthy Subjects
by: Kim YK, et al.
Published: (2021-04-01) -
Lobeglitazone, a Novel Peroxisome Proliferator-Activated Receptor γ Agonist, Attenuates Renal Fibrosis Caused by Unilateral Ureteral Obstruction in Mice
by: Kwi-Hyun Bae, et al.
Published: (2017-02-01) -
A pharmacokinetic and pharmacodynamic drug interaction between rosuvastatin and valsartan in healthy subjects
by: Jung JA, et al.
Published: (2015-03-01) -
Evaluation of pharmacokinetics of warfarin from validated pharmacokinetic-pharmacodynamic model
by: Kannan Sridharan, et al.
Published: (2021-01-01) -
Clinical and genetic determinants of warfarin pharmacokinetics and pharmacodynamics during treatment initiation.
by: Inna Y Gong, et al.
Published: (2011-01-01)